供货705万，给医生回扣247万！国家医保局一个月曝光四起回扣案

Core Viewpoint - The National Healthcare Security Administration (NHSA) has exposed multiple cases of kickbacks in the medical industry, particularly in the fields of pharmaceuticals and medical supplies, highlighting the prevalence of corruption and its impact on healthcare costs and competition [3][4]. Group 1: Case Details - A case involving Li, the director of an orthopedic hospital in Shaanxi, revealed that he illegally accepted a total of 2.7205 million yuan in kickbacks, primarily from orthopedic supplies [1]. - Li received 2.469 million yuan from supplier Jia, who promised a 35% kickback on the total supply amount, leading to the procurement of supplies worth 7.0546 million yuan from July 2014 to March 2017 [1]. - Another supplier, Sun, paid Li 231,600 yuan in kickbacks from January 2018 to January 2019, with a total supply value of 772,200 yuan, despite Li lacking the authority to choose suppliers [2]. Group 2: Implications and Responses - The NHSA stated that medical commercial bribery undermines fair competition and increases healthcare costs, as kickbacks can inflate the prices of medical products by at least one-third [3]. - The NHSA plans to guide local healthcare authorities in evaluating the creditworthiness of involved companies and enforce corrective measures against those that fail to comply [3]. - In 2023, the NHSA has already exposed four kickback cases, indicating a significant issue within the pharmaceutical and medical supply sectors [3].